To evaluate the antibacterial activity of Kurarinone against MSSA ATCC 25923, results showed significant antibacterial activity
J Adv Res. 2024 Mar;57:197-212
MSSA ATCC 29213
7.8 µg/mL
18 hours
To evaluate the antibacterial activity of Kurarinone against MSSA ATCC 29213, results showed significant antibacterial activity
J Adv Res. 2024 Mar;57:197-212
MRSA (USA300)
7.8 µg/mL
18 hours
To evaluate the antibacterial activity of Kurarinone against MRSA, results showed significant antibacterial activity
J Adv Res. 2024 Mar;57:197-212
HaCaT cells
50 μM
6 hours
To evaluate the effect of Kurarinone on HO-1 expression, results showed that Kurarinone induced HO-1 expression.
Antioxidants (Basel). 2020 Sep 9;9(9):842
RAW264.7 cells
50 μM
6 hours
To evaluate the effect of Kurarinone on HO-1 expression, results showed that Kurarinone induced HO-1 expression.
Antioxidants (Basel). 2020 Sep 9;9(9):842
PC3 cells
50 μM
6 hours
To evaluate the effect of Kurarinone on HO-1 mRNA expression, results showed that Kurarinone significantly increased HO-1 mRNA expression.
Antioxidants (Basel). 2020 Sep 9;9(9):842
BEAS-2B cells
5, 10, 15, 20 mg/mL
12, 24, 48 hours
To evaluate the toxicity of Kurarinone on BEAS-2B cells. Results showed that Kurarinone had low toxicity on BEAS-2B cells.
Front Pharmacol. 2018 Mar 23;9:252
NCI-H1975 cells
5, 10, 15, 20 mg/mL
12, 24, 48 hours
To evaluate the inhibitory effect of Kurarinone on the proliferation of NCI-H1975 cells. Results showed that Kurarinone had significant cytotoxicity against NCI-H1975 cells.
Front Pharmacol. 2018 Mar 23;9:252
A549 cells
5, 10, 15, 20 mg/mL
12, 24, 48 hours
To evaluate the inhibitory effect of Kurarinone on the proliferation of A549 cells. Results showed that Kurarinone inhibited the proliferation of A549 cells in a time- and dose-dependent manner.
Front Pharmacol. 2018 Mar 23;9:252
CDLN cells
20 μg/ml
72 hours
To investigate the effect of KU on Th17 cell differentiation and Rac1 expression in CDLN cells. Results showed that KU significantly inhibited Th17 cell differentiation and Rac1 expression.
J Adv Res. 2025 Mar;69:381-398
Peripheral blood mononuclear cells (PBMCs)
10 and 20 μg/ml
72 hours
To evaluate the effect of KU on inflammatory cytokine production in PBMCs. Results showed that KU significantly inhibited Th17 cell differentiation and Rac1 expression, and reduced inflammatory cytokine production.
J Adv Res. 2025 Mar;69:381-398
B16F10 cells
5 and 10 μM
48 hours
Enhanced intracellular tyrosinase activity and stimulated melanin production
Front Pharmacol. 2024 Jul 10;15:1422310
Kurarinone/苦参黄素 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Zebra fish
Zebra fish larvae
20 μM
48 hours
Stimulated melanogenesis by 36.9%
Front Pharmacol. 2024 Jul 10;15:1422310
C57BL/6J mice
Experimental autoimmune uveitis (EAU) model
Intraperitoneal injection
10, 20, 40 mg/kg
Once daily for 14 days
To evaluate the therapeutic effect of KU on EAU model mice. Results showed that KU significantly alleviated EAU symptoms, reduced retinal inflammatory cell infiltration, and regulated Th17/Treg balance.
J Adv Res. 2025 Mar;69:381-398
ICR mice
MRSA skin wound infection model
Topical administration
7.8 mg/kg
Once daily for 14 days
To evaluate the therapeutic effect of Kurarinone on MRSA skin wound infection, results showed significant promotion of wound healing and reduction of bacterial load
J Adv Res. 2024 Mar;57:197-212
BALB/c mice
Bleomycin-induced pulmonary fibrosis model
Oral
5 mg/kg and 10 mg/kg
Five times a week from day 7 to day 27 after bleomycin administration
Kurarinone improved mechanical lung function, reduced collagen accumulation in lung tissues, and suppressed phosphorylation of Smad2/3 and AKT in bleomycin-induced pulmonary fibrosis mice.
Int J Mol Sci. 2021 Aug 4;22(16):8388
C57BL/6 mice
TNBS-induced colitis model
Intraperitoneal injection
125 mg/kg/day
Once daily for 7 days
KAR significantly alleviates TNBS-induced colitis symptoms, including reduced weight loss, lower disease activity index, improved colonic tissue damage, decreased inflammatory cell infiltration, protection of goblet cells and tight junction structures, and restoration of gut microbiota balance. Mechanistically, KAR suppresses Th17 cell response and promotes IL-10 production via Blimp-1
Front Immunol. 2025 May 1;16:1587479
BALB/c nude mice
A549 xenograft model
Intraperitoneal injection
20 and 40 mg/kg/day
Once daily for 27 days
To evaluate the inhibitory effect of Kurarinone on the growth of A549 xenograft tumors in vivo. Results showed that Kurarinone significantly inhibited tumor growth without apparent toxicity.
Front Pharmacol. 2018 Mar 23;9:252
Mice
MPTP-induced PD model
5, 10, and 20 mg/kg
Kurarinone dose-dependently alleviated MPTP-induced behavioral deficits and dopaminergic neurotoxicity, including the losses of neurotransmitters and tyrosine hydroxylase (TH)-positive cells. Furthermore, kurarinone attenuated MPTP-mediated neuroinflammation by suppressing the activation of microglia involved in the nuclear factor kappa B signaling pathway.
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2118818119
DBA/1 mice
Collagen-induced arthritis (CIA) model
Oral
100 mg/kg/day
Once daily for 21 days
Reduced arthritis symptoms, decreased inflammatory cytokine levels, inhibited Th1 and Th17 cell responses, and reduced oxidative stress
搜索
